BACKGROUND Mohs micrographic surgery (MMS) with melanoma antigen recognized by T-cell (MART-1) immunostaining is an effective treatment of cutaneous melanoma.
T he incidence of cutaneous melanoma (CM) continues to increase at a fast rate with the number of new cases rising annually across all age groups. 1 Therefore, identifying safe and costeffective therapy is increasingly important. According to the American Academy of Dermatology guidelines, "the primary treatment modality for CM is surgical excision" and "the primary goal of surgical excision of melanoma, of any thickness, is to achieve histologically negative margins and prevent local recurrence because of persistent disease." 2 The challenge nowadays lies in finding the most effective way to confirm histologically negative margins, and the ideal approach to achieve this continues to be a matter of debate. Multiple surgical modalities for CM, including wide surgical excision, staged excision, and Mohs micrographic surgery (MMS), have been reported with variable success. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Mohs surgery offers relevant advantages over traditional or staged excision. It examines 100% of the surgical margins, and it is a time-efficient process completed in 1 day, allowing same-day confirmation of tumor-free margins before reconstruction. Furthermore, it is a cost-effective method in which surgical, technical, and pathologic costs are bundled. 18, 19 The most common method used today for the treatment of CM is wide local excision with traditional (vertical sectioning) pathology examination. The most significant weakness of this method is that it allows examination of less than 1% of the margins. 20 Moreover, studies have demonstrated that breadloaf cross sections of excised melanoma in situ (MIS) specimens at 4-mm intervals have only a 19% chance of detecting a positive margin and recommend the use of complete en face examination of the surgical margins. 21 The use of Mohs surgery for melanoma has been reported by multiple authors who have demonstrated a high success rate, usually defined as equivalent or superior melanoma-specific survival rates and equivalent or lower local recurrence and metastasis rates, when compared to historical controls treated with wide surgical excision. 4, 5 There is little or no evidencebased controversy about the value of Mohs surgery. However, despite the evidence in support of MMS, only a minority of Mohs surgeons use this technique in the treatment of melanoma because of the perceived difficulty of interpreting atypical melanocytic proliferations on frozen section slides.
One of the most important advances in margin examination has been the use of immunostain. Their use, particularly melanoma-associated antigen recognized by T cells (MART-1), has revolutionized the interpretation of surgical margins when treating melanoma. Its melanocyte specificity and easy distinction from surrounding background tissue makes MART-1 frozen sections easy to interpret and a significant advance in the accurate determination of surgical margins. 7, 22, 23 The use of MART-1 on frozen sections during Mohs surgery has been proven to offer a more precise evaluation of the surgical margins than hematoxylin and eosin (H&E) staining of permanent sections, and to provide equivalent information from that obtained in MART-1 permanent sections. 24 Characterization and definitions of a positive surgical margin, as compared with normal, sun-damaged skin, have additionally contributed to overcoming the challenging task of evaluating melanoma on frozen sections. 25, 26 The authors evaluated their experience from a single institution using MART-1 immunostain to test the hypothesis that MMS with MART-1 would provide more accurate removal of melanoma than conventional surgery. The present study reports the results of the largest cohort to date on the use of MMS with MART-1 immunostain in the surgical management of invasive and in situ melanomas. Survival and local recurrence rates are reported and compared with those of historical controls.
Methods
In this retrospective study, patients with biopsyproven invasive and in situ melanoma who were referred for Mohs excision from January 2003 through December 2011 were assessed. A prospective database established in 1982 that includes patient and tumor characteristics was used. MART-1 immunostaining was begun in 2003; thus, only patients in whom MART-1 immunostain were used were included. Patients with an equivocal diagnosis of melanoma (e.g., moderate to severely atypical dysplastic nevi) or desmoplastic melanoma (n = 5) were excluded. The surgical methods, as well as the technique of MART-1 immunostaining, have been previously described. [4] [5] [6] 22 Positive margins were identified as those having one or more of the following 5, 6, 25, 26 : (1) nests of at least 3 atypical melanocytes, (2) dermoepidermal junction, (3) confluence of more than 9 adjacent melanocytes, (4) "vertical stacking" of melanocytes, (5) melanocytic hyperplasia significantly different in one area as compared with the rest of the margin, and (6) presence of nests of atypical cells in the dermis (Figure 1 ). Isolated findings, such as mild to moderate confluence of melanocytes, focal pagetosis, superficial follicular extension (<1 mm), and mild or moderate cytologic atypia, were not interpreted as melanoma because these can be observed in nonlesional, sun-exposed skin. 24, 25 Follow-Up, Outcome, and Analyses Patients with MIS were followed up annually, and patients with invasive melanoma were followed up at least semiannually or more depending on the Breslow thickness. Patients who did not receive follow-up examination, either in our office or with their primary dermatologist after MMS, were contacted by phone. The cause of death of patients who died during the follow-up period was obtained from the patient's primary care physician or family member.
Local recurrence was defined in 2 ways. First, the reappearance of a tumor within or adjacent to the surgical scar, with an intraepidermal component, was used as the definition of inadequate initial excision. Second, it was defined as any recurrence within 2 cm of the surgical scar, which may include satellite metastasis, and was used to be able to compare local recurrence rates to those of historical controls, although known not to be a precise measure of surgical success. Mortality was disease-specific and defined as mortality from metastatic melanoma.
Cases were stratified using updated American Joint Commission for Cancer (AJCC) Breslow thickness criteria, 27 and the Kaplan-Meier method was used to calculate 5-year local recurrence and disease-specific survival rates after MMS with MART-1 immunostain. Earlier, Breslow thickness criteria 28 were used to restratify the tumors to compare local recurrence rates and disease-specific survival rates to those of historical controls.
Margins required to completely excise melanomas were calculated based on AJCC Breslow thickness, tumor location and tumor size. The minimum surgical margin required to completely excise 97% of all tumors was calculated for each subgroup. 29 
Statistical Analysis
Descriptive analysis was performed to characterize the authors' study group. The authors evaluated the statistical association between the following variables: thickness, size, and location with the margins of excision. The assessment of the statistical significance of these associations between categorical variables was performed using either chi-squared probability distribution or Fisher exact test, as considered appropriate. For quantitative variables, the Student's t-test was performed to assess the mean difference between two groups. p < .05 was considered statistically significant.
Local recurrence rates, disease-specific survival rates, and mortality rates were described using the Kaplan-Meier method. The local recurrence rate, including satellite metastasis, was calculated for MIS and invasive melanoma and compared with those receiving conventional treatment (control groups) in a series of studies. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] The authors also compared the survival rates of patients treated with MMS and MART-1 immunostain with those of 15,798 patients treated with conventional treatment using wide local excision. 43 Patients lost to follow-up (n = 513), mostly because they had outdated contact information, were excluded from the recurrence, survival, and mortality analysis. STATA (Version 12.0, College Station, TX) was used to perform data management and all statistical analyses.
Results

Patient Population
From 2003 to 2011, 1,982 patients with 2,114 melanomas were treated with MMS and MART-1 immunostain. The mean patient age was 66 years (range: 12-99); most of the patients were male (60.7%).
Patient and tumor characteristics are detailed in Table  1 . The mean time of follow-up, excluding those patients who were lost to follow-up, was 3.73 (62.40) years (minimum = 0 years, maximum = 9.54 years).
Among all the melanomas treated, a total of 1,882 (89.1%) were primary melanomas, whereas 230 (10.9%) had been previously treated. The most common location was the face (44.7%), followed by the extremities (22.3%) and trunk (21.5%). Of note, 53.2% of the melanomas were located on the head and neck. The mean size of the tumor (i.e., diameter) was 1.66 cm (60.96). Among the invasive tumors, the mean Breslow thickness was 0.9 mm (61.1 mm). In situ and thin (#1 mm) melanomas comprised 90.5% of the melanomas treated.
Surgical Margins
Most melanomas (76%) were excised in 1 stage. The mean margin for excision overall was 7.2 mm (63.3 mm). A significant difference in margin size for excision was observed between primary and recurrent melanomas (6.86 mm vs 9.57 mm, respectively; p < .0001). Also, the margin size was significantly different between melanomas on the head and neck and other locations (7.56 mm vs 6.69 mm, respectively; p < .0001). The margin size did not show significant difference between in situ and 
invasive melanomas (7.10 mm vs 7.23 mm, respectively; p = .39).
The cumulative margin required for complete excision among primary melanomas according to their thickness is shown in Figure 2 . Approximately 82% of these melanomas were completely excised with a #6-mm margin. Increasing margin size showed a higher proportion of melanomas being completely excised; however, no significant difference was observed between the different Breslow thickness subgroups (p > .05).
The size of the surgical margin needed to remove the melanoma completely was significantly related to tumor location and size (p < .001). Margins of #9 mm successfully removed 97% (95% CI: 96-98) of the melanomas on the trunk and extremities. However, a similar proportion of melanomas were removed using margins #12 mm on the hands and feet (98%, 95% CI: 95-101) and #15 mm on the head and neck (97%, 95% CI: 96-98) (Figure 3) . Similarly, when all cases were analyzed by tumor size, a #9-mm margin completely removed 95% (95% CI: 92-97) of melanomas <1 cm in diameter, whereas larger margins were required for larger tumors (data not shown).
Local Recurrence Rates
There were a total of 11 local recurrences, as defined by the reappearance of tumor within or adjacent to the surgical scar, 7 in primary tumors, and 4 in recurrent tumors treated with MMS using MART-1 immunostain ( Table 2 ). The crude local recurrence rates are detailed in Table 3 . All but one patient with recurrent disease were treated with MMS and MART-1 immunostain and were free of disease at the last follow-up. One patient chose wide local excision and was also free of disease at the last follow-up.
The authors compared their results with those of historical controls with large cohorts and valid followup. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] The local recurrence rate for the authors' group was calculated to include satellite metastasis because historical controls in a series of studies for comparison used the same definition. Among MISs and invasive melanomas, the recurrence rate was significantly lower in patients treated with MMS and MART-1 immunostain than those treated with conventional wide local excision (Table 4 ). Local recurrence rates by location were lower for patients treated with MMS using MART-1 immunostain than historical controls. Among some of the series analyzed for melanomas on the head and neck or the trunk and extremities, recurrence rates were significantly lower with MART-1 immunostain than with wide local excision ( Table 5 ).
Overall and Disease-Specific Survival and Mortality
The five-year Kaplan-Meier local recurrence and disease-specific survival rates for primary tumors treated with MMS and MART-1 immunostain were 0.59% 6 0.30% and 98.53% 6 0.42%, respectively (Table 6; Figure 4 ).
During the maximum follow-up period of 9.54 years, there were a total of 121 deaths for an overall mortality of 7.6% (121/1,601). Of these, 16 were due to For each thickness subgroup, the five-year Kaplan-Meier survival rates after MMS were compared to those of standard surgery. Mohs micrographic surgery achieved statistically significant higher five-year survival rates than those of the control group in 4 of the 5 groups compared ( Figure 5 ).
Discussion
The evidence in this study confirms that MMS with MART-1 immunostain is an effective treatment of MIS and invasive melanoma. Previous studies of MMS for the treatment of CM, with or without the use of immunostain, support these findings. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] A recently published series with a large cohort and long-term follow-up also demonstrates a very low recurrence rate (0.34%) with MMS and MART-1 immunostain. 17 We now have two large studies of adequate follow-up with separate investigators and distinct training validating similar results (recurrence rates, <1%), significantly better than wide surgical excision. 17 When compared to traditional wide local excision for CM, MMS offers the ability to excise melanoma completely with histologically negative margins and therefore offers the highest cure rates and the best tissue conservation of any surgical method. Additionally, same-day confirmation of negative margins before reconstruction represents a significant advantage.
Frozen-Section Interpretation
The authors have previously reported that frozen sections have a sensitivity of 100% in detecting melanoma in the surgical margins when present and a specificity of 90%. 44 Further studies have found a 100% concordance between frozen sections and formalin-fixed, paraffin-embedded permanent sections. 12 Immunohistochemical stains considerably aid in the detection of melanocytes and residual melanoma on permanent sections, as well as frozen sections. 45 MART-1 has been shown to be effective and useful in the identification of residual tumor within MMS margins, demonstrating superior sensitivity than Mel-5 and superior specificity than S-100 immunostain. 7, 8 The low recurrence rate in the present study, combined with the fact that the authors were able to achieve narrow margins (<1 cm) in 94% of the cases, validate the accuracy of frozen sections with MART-1 immunostain in detecting melanoma at the margins. It is our experience and that of others that MART-1 immunostain aid in the speed and certainty of reading frozen sections as compared to routine H&E-stained frozen sections, and determination of a positive or negative margin can often be performed on low-power examination. 7, 46 Variations in the density of melanocytes along the margin also aid when interpreting margin status, something that cannot be assessed with vertical sectioning.
Surgical Margins
The evidence to date confirms that very wide surgical margins aimed at removing satellite micrometastasis do not offer a survival advantage or reduce local recurrence rates. 41, [47] [48] [49] [50] The authors' data also demonstrate that margins that are narrower, but also confirmed to be histologically negative, than 34 .003 48/638 (7.5) 35 <.0001 *Includes satellite metastasis. Mean follow-up = 3.71 years; mean time to recurrence = 3.15 years (SD = 2.41 years). †Any tumor growth that reappeared in the scar, under the skin graft, or within 3 cm of the margins of the wide excision. Mean follow-up = 3.5 years, 30 3.2 years, 31 3 years, 32 8 years, 33 3 years, 34 "standard" margins do not increase the risk of recurrence or negatively affect survival.
In the present study, 82% of all melanomas were completely excised with #6-mm margins; 94% with #9-mm margins; and 97% with #12-mm margins. Similarly, for MIS and thin melanoma, which comprised most of the authors' sample, #12-mm margins were required to excise 97% of the tumors, although in the present study, there was no significant rela-tionship between tumor thickness and the width of excision merging necessary for histologically tumorfree margins. The authors' data show that MIS must be treated with the same margin as thin melanomas, which differs from what is suggested by the National Institute of Health consensus panel (i.e., 5-mm margin is adequate for MIS). 51
The evidence in this study is useful to propose surgical margins for traditional wide local excision. In this 67. 50 6 20.74 Recurrences: MIS, n = 3; <1 mm, n = 1; 1.01 to 2.00 mm, n = 0; 2.01 to 4.00 mm, n = 1; >4.00 mm, n = 0; excluding lost to follow-up.
DSS, disease-specific survival; LR, local recurrence (defined as recurrence within or immediately adjacent to scar because of inadequate excision and excludes local recurrences from satellite and in-transit metastasis). Most of the patients who required >1 cm margin had melanomas either on the head and neck or hands and feet, similar to previous findings, confirming that tumors on these locations often have wider subclinical extensions than melanomas on the trunk or proximal extremities. 4, 5 However, MMS with MART-1 immunostain allowed the authors to successfully remove 77% and 85% of melanoma on the head and neck and hands and feet, respectively, with #6-mm margins and to identify those outlier patients who required wider margins to minimize local recurrence. This demonstrates the substantial tissue-conserving value of Mohs surgery in an area where conventional wide margins often cannot be taken because of cosmetic or functional limits.
The authors' data also confirm that the margins recommended for invasive melanomas on the trunk and proximal extremities published in 5 randomized controlled trials are reasonable when margins are determined without immediate, complete microscopic margin evaluation. 41, [47] [48] [49] [50] These studies evaluated only trunk and proximal extremities and cannot be extrapolated to guidelines for the head and neck. For this practice gap, the authors show that wider margins are necessary for invasive melanomas on the head and neck as compared to the trunk and extremities, and thus recommend a 1.5-and 1.2-cm margin for CM on the head and neck and hands and feet, respectively. 
Local Recurrences and Disease-Specific Survival
The efficacy of Mohs surgery is confirmed by demonstrating a significantly lower recurrence rate than historical controls. This was achieved using microscopic margin evaluation for tumor clearance, rather than the use of predetermined, wider margins. The authors' local recurrence rate was very low; 0.56 6 0.40 and 0.66 6 0.47 for MIS and invasive melanoma, respectively. All but one of the authors' local recurrences appeared on the head and neck, a location associated with very high local recurrence rates. [30] [31] [32] [33] [36] [37] [38] [39] [40] [41] 52 Reasons for the authors' higher local recurrence rate may be the inherent difficulty distinguishing early melanoma from normal, sun-damaged skin of the head and neck, as well as a referral bias cohort with treatment of very challenging and/or previously treated tumors. In either case, the rate was low and MMS provides a significant advantage with a reduced rate of local recurrence.
The efficacy of MMS for the treatment of melanoma is also demonstrated by the noninferiority of melanomaspecific survival. The finding of a higher melanomaspecific survival may be explained, in part, as a consequence of decreased local recurrence.
A previous study has shown that 23% of MIS recurrences appear as invasive disease with a mean Breslow thickness of approximately 1 mm. 53 In this study, the MIS local recurrence rate for conventional surgery is 20 times higher than that of MMS (0.41 vs 9.0 31, 32 ). Thus, for every 1,000 patients, conventional surgery will result in 90 recurrences and 21 (23%) of these patients will reappear with melanomas of approximately 1 mm. One of these patients is predicted to die of recurrent melanoma that may not be seen in the MMS group. Similarly, in the invasive melanoma group, for every 1,000 patients treated with conventional surgery, 30 (3%) will develop recurrent disease and 10 (33%) will reappear with melanoma deeper than the thickness of the original primary. 53 One or two of these patients can be predicted to die of recurrent disease. Thus, although the magnitude of a survival benefit for MMS may be small, it may be reflected in the melanoma-specific survival.
The large cohort of patients and the length of followup demonstrate the main strengths of this study. However, limitations of this study include that it is a single-site retrospective study with lack of a control arm. Also, some of the local recurrence data relied on patient reporting, which could cause a false low rate of local recurrence. A prospective, multicenter, longterm follow-up study with a control arm using traditional wide local excision would greatly help further validate these findings.
Conclusion
The authors' study demonstrates the accuracy and effectiveness of MART-1 immunostaining when used for margin evaluation during MMS for melanoma. The authors show the ability to completely remove melanoma as demonstrated by their low local recurrence rates. Furthermore, the authors' have shown the advantage of being able to remove melanoma in most cases with more tissue-conserving margins than the standard margins recommended for wide local excision. Melanomaspecific survival is at least as high as wide excision. With lower recurrence rates after MMS, there is a theoretical survival advantage due to the fact that more melanomas recur after standard surgery with an increased Breslow thickness and increased risk of metastasis.
Surgical margin data help to establish evidence-based margins for the head and neck melanomas and MIS and validates the randomized controlled trials margin data for trunk and extremity melanomas. 41, [47] [48] [49] [50] Finally, the data presented should be considered in future revisions of the Appropriate Use Criteria for Mohs Surgery regarding melanoma in the future. 54 
